<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Andrea Ungar - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/andrea-ungar/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/andrea-ungar/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Fri, 01 Mar 2019 16:29:07 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>Andrea Ungar - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/andrea-ungar/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Rivaroxaban: protezione pazienti con malattie cardiovascolari</title>
		<link>https://www.newpharmaitaly.it/rivaroxaban-protezione-pazienti-con-malattie-cardiovascolari/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Fri, 01 Mar 2019 16:29:07 +0000</pubDate>
				<category><![CDATA[Innovazione]]></category>
		<category><![CDATA[Andrea Ungar]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Congresso Conoscere e Curare il Cuore]]></category>
		<category><![CDATA[firenze]]></category>
		<category><![CDATA[malattie cardiovascolari]]></category>
		<category><![CDATA[Medicina]]></category>
		<category><![CDATA[Ospedale Careggi]]></category>
		<category><![CDATA[rivaroxaban]]></category>
		<category><![CDATA[simposio]]></category>
		<category><![CDATA[Studio Compass]]></category>
		<guid isPermaLink="false">https://www.newpharmaitaly.it/?p=3541</guid>

					<description><![CDATA[<p>A Rivaroxaban è dedicato un Simposio organizzato da Bayer all’interno del Congresso Conoscere e Curare il Cuore in corso a Firenze Negli ultimi vent’anni l’incremento della popolazione anziana ha determinato un aumento delle patologie croniche, tra cui quelle del sistema cardio-vascolare. In Italia, ad esempio, l’ictus è responsabile ogni anno del 10 &#8211; 12% di [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/rivaroxaban-protezione-pazienti-con-malattie-cardiovascolari/">Rivaroxaban: protezione pazienti con malattie cardiovascolari</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
